Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for Monday, May 20, 2024, at 2:00 p.m. ET. The presentation will be webcast live and available for replay for approximately 30 days on the company's investor website.
ADC Therapeutics SA, listed as NYSE: ADCT, will have its CEO, Ameet Mallik, participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The presentation will be live-streamed on the company's website, with a replay available for 30 days.
ADC Therapeutics SA (NYSE: ADCT) has announced an underwritten offering of 13,411,912 common shares at $4.900 per share and pre-funded warrants to purchase 8,163,265 common shares at $4.812 per pre-funded warrant, expecting to raise approximately $105.0 million. The offering is set to close on May 8, 2024, with Jefferies, Guggenheim Securities, and Cantor as joint book-running managers. A registration statement has been filed with the SEC, and more details can be found on the SEC's website.
ADC Therapeutics reported a net sales of $17.8 million for ZYNLONTA® in 1Q 2024 with total operating expenses decreasing 25%; LOTIS-7 dose escalation completed and 2L+ DLBCL expansion initiated; MZL IIT Phase 2 data showed 13 CR and 1 PR patients; next-generation ADC platform showcased promising preclinical data in NaPi2b, Claudin-6, PSMA, and ASCT2; cash and cash equivalents at $234.3 million, expecting runway until Q4 2025.
ADC Therapeutics announced initial data from an investigator-initiated Phase 2 clinical trial of ZYNLONTA® in patients with relapsed/refractory marginal zone lymphoma. Of the 15 patients evaluated, 13 achieved a complete response and one achieved a partial response. The drug was well-tolerated, with two patient discontinuations due to toxicity, both remaining in complete response. The study was presented at the Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Scientific Workshop.
ADC Therapeutics SA announced grants of options to purchase 147,600 common shares to four new employees on May 1, 2024, as part of an Inducement Plan. The grants were approved by the Compensation Committee to motivate employees to perform at their best. The shares will vest over four years, contingent on continued employment.
ADC Therapeutics SA (NYSE: ADCT) will host a conference call and webcast on May 6, 2024, to report Q1 2024 financial results and provide pipeline updates. Registrants can access the call via dial-in or webcast. The company aims to share recent progress on key pipeline catalysts.
Summary not available.
Summary not available.
Summary not available.